Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Herpes zoster (HZ), or shingles, is caused by the reactivation of latent varicella-zoster virus (VZV) from the sensory ganglia when VZV-specific T-cell immunity is decreased because of aging or immunosuppression. In the present study, we developed HZ DNA vaccine candidates encoding VZV proteins and cytokine adjuvants, such as IL-7 and IL-33. We immunized C57BL/6 mice with DNA plasmids encoding VZV glycoprotein E (gE), immediate early (IE) 63, or IE62 proteins and found that robust VZV protein-specific T-cell responses were elicited by HZ DNA vaccination. Co-administration of DNA plasmids encoding IL-7 or IL-33 in HZ DNA vaccination significantly enhanced the magnitude of VZV protein-specific T-cell responses. Protective immunity elicited by HZ DNA vaccination was proven by challenge experiments with a surrogate virus, vaccinia virus expressing gE (VV-gE). A single dose of HZ DNA vaccine strongly boosted gE-specific T-cell responses in mice with a history of previous infection by VV-gE. Thus, HZ DNA vaccines with IL-7 and IL-33 adjuvants strongly elicit protective immunity.
Abstract
Herpes zoster (HZ), or shingles, is caused by the reactivation of latent varicella-zoster virus (VZV) from the sensory ganglia when VZV-specific T-cell immunity is decreased because of aging or immunosuppression. In the present study, we developed HZ DNA vaccine candidates encoding VZV proteins and cytokine adjuvants, such as IL-7 and IL-33. We immunized C57BL/6 mice with DNA plasmids encoding VZV glycoprotein E (gE), immediate early (IE) 63, or IE62 proteins and found that robust VZV protein-specific T-cell responses were elicited by HZ DNA vaccination. Co-administration of DNA plasmids encoding IL-7 or IL-33 in HZ DNA vaccination significantly enhanced the magnitude of VZV protein-specific T-cell responses. Protective immunity elicited by HZ DNA vaccination was proven by challenge experiments with a surrogate virus, vaccinia virus expressing gE (VV-gE). A single dose of HZ DNA vaccine strongly boosted gE-specific T-cell responses in mice with a history of previous infection by VV-gE. Thus, HZ DNA vaccines with IL-7 and IL-33 adjuvants strongly elicit protective immunity.
참고문헌 (41)
- Zerboni L, "Molecular mechanisms of varicella zoster virus pathogenesis", Nat Rev Microbiol, 12, pp.197~210 (2014)[DOI]
- Gershon AA, "Pathogenesis and current approaches to control of varicella-zoster virus infections", Clin Microbiol Rev, 26, pp.728~743 (2013)[DOI]
- Yawn BP, "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction", Mayo Clin Proc, 82, pp.1341~1349 (2007)[DOI]
- Forbes HJ, "Quantification of risk factors for herpes zoster: population based case-control study", BMJ, 348, pp.g2911~ (2014)
- Harpaz R, "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 57, pp.1~30 (2008)
- Weinberg A, "Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine", J Infect Dis, 200, pp.1068~1077 (2009)[DOI]
- Leroux-Roels I, "A phase 1", 2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults, 2012, pp.206, 1280~1290
- Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults", N Engl J Med, 352, pp.2271~2284 (2005)[DOI]
- Schmader KE, "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years", Clin Infect Dis, 54, pp.922~928 (2012)[DOI]
- Tseng HF, "Declining effectiveness of herpes zoster vaccine in adults aged TEX>$\geq$<", TEX>60 years, 2016, pp.213, 1872~1875
- Qi Q, "Defective t memory cell differentiation after varicella zoster vaccination in older individuals", PLoS Pathog, 12, pp.e1005892~ (2016)[DOI]
- Cunningham AL, "Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older", J Infect Dis, 217, pp.1750~1760 (2018)[DOI]
- Berkowitz EM, "Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1", 2a randomized, placebo-controlled study, 2015, pp.211, 1279~1287
- Stadtmauer EA, "A phase 1", 2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients, 2014, pp.124, 2921~2929
- Chlibek R, "Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults", Vaccine, 34, pp.863~868 (2016)[DOI]
- Kutzler MA, "DNA vaccines: ready for prime time?", Nat Rev Genet, 9, pp.776~788 (2008)[DOI]
- Ferraro B, "Clinical applications of DNA vaccines: current progress", Clin Infect Dis, 53, pp.296~302 (2011)[DOI]
- Trimble CL, "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2", 3: a randomised, double-blind, placebo-controlled phase 2b trial, 2015, pp.386, 2078~2088
- Tiriveedhi V, "Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer", Clin Cancer Res, 20, pp.5964~5975 (2014)[DOI]
- Kalams SA, "Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery", J Infect Dis, 208, pp.818~829 (2013)[DOI]
- Jones S, "DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial", Vaccine, 27, pp.2506~2512 (2009)[DOI]
- Fry TJ, "A potential role for interleukin-7 in T-cell homeostasis", Blood, 97, pp.2983~2990 (2001)[DOI]
- Schluns KS, "Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo", Nat Immunol, 1, pp.426~432 (2000)[DOI]
- Levy Y, "Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment", J Clin Invest, 119, pp.997~1007 (2009)
- Sportes C, "Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy", Clin Cancer Res, 16, pp.727~735 (2010)[DOI]
- Perales MA, "Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation", Blood, 120, pp.4882~4891 (2012)[DOI]
- 박수형, "Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys", Immune Network, 10(6), pp.198~205 (2010), 대한면역학회
- Sin JI, "Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and", or Th2-type immune responses in vivo, 2000, pp.7, 751~758
- Villarreal DO, "Interleukin 33: a switch-hitting cytokine", Curr Opin Immunol, 28, pp.102~106 (2014)[DOI]
- Villarreal DO, "Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity", Cancer Res, 74, pp.1789~1800 (2014)[DOI]
- Villarreal DO, "Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model", Vaccine, 33, pp.4313~4320 (2015)[DOI]
- Malavige GN, "Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors", Clin Exp Immunol, 152, pp.522~531 (2008)[DOI]
- Frey CR, "Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination", J Infect Dis, 188, pp.40~52 (2003)[DOI]
- Jones L, "Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus", Eur J Immunol, 37, pp.3393~3403 (2007)[DOI]
- 최윤석, "Relationship between Poor Immunogenicity of HLA-A2-Restricted Peptide Epitopes and Paucity of Naïve CD8＋ T-Cell Precursors in HLA-A2-Transgenic Mice", Immune Network, 14(4), pp.219~225 (2014), 대한면역학회
- Degen W, "Immunopotentiators in Modern Vaccines", pp.65~84 (2017), Elsevier
- Wang L, "Efficacy of varicella (VZV) vaccination: an update for the clinician", Ther Adv Vaccines, 4, pp.20~31 (2016)[DOI]
- Lee H, "Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of hepatitis C virus infection", Sci Rep, 7, pp.43531~ (2017)[DOI]
- Sun Y, "Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation", Gene Ther, 24, pp.408~415 (2017)[DOI]
- Gershon AA, "Advances in the understanding of the pathogenesis and epidemiology of herpes zoster", J Clin Virol, 48(Suppl 1), pp.S2~S7 (2010)[DOI]
- Dendouga N, "Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice", Vaccine, 30, pp.3126~3135 (2012)[DOI]